September 19, 2022: Azelis, a prominent worldwide innovation service provider in the food additives and specialty chemicals sector, is pleased to announce that it has entered into a new distribution deal with the esteemed specialty chemical manufacturer Clariant. Customers of Azelis in Austria, Germany, and Switzerland now have instant access to the whole line of active pharmaceutical ingredients (API) and excipients from Clariant.
March 8, 2022: At its active pharmaceutical ingredients (API) manufacturing facility in Nansha, China, Lonza, a global manufacturing partner to the biotech, nutrition, and pharmaceutical industries, today announced the completion of a laboratory expansion. With regard to the clinical supply of highly-potent APIs (HPAPI), the expansion primarily aimed to increase the capabilities and capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5471
Published Date: Dec 22, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the growth of the market are growth in number of women menstruating, rise in need for growth in drug development, and surge in prevalence of musculoskeletal disorders in pediatrics.
The market size of ibuprofen API is anticipated to attain a CAGR of 3% over the forecast period, i.e., 2024-2036.
The major players in the market are Azelis, Lonza, BIOCAUSE Inc., IOL Chemicals and Pharmaceuticals Limited and others.
The arthritis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.